The Medigene Share
The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000.
Investors & Media
Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.
Latest News
Medigene presents compelling in vivo data for use of PD1-41BB-enhanced TCR-T cells against solid tumors
Events
12
Aug 2021
6-Month Report 2021
31 Aug - 02 Sep
2021
CAR-TCR Summit 2021
13 - 15
Sep 2021
H.C. Wainwright 23rd Annual Global Investment Conference
20 - 24
Sep 2021
10th Baader Investment Conference
11
Nov 2021
Quarterly Statement Q3 2021
16 - 18
Nov 2021
12th Annual Jefferies Global Healthcare Conference
16 - 18
Nov 2021
Cell Immunotherapies for Solid Tumors Summit
04 - 06
May 2022
Advanced Therapies
07 - 08
Sep 2022
Stifel London Cross Sector Insight Conference
Corporate Governance
Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.
Contact person
Dr. Anna Niedl
Vice President Investor Relations & Corporate Communications
investor(at)medigene.com
Phone: +49 89 2000 3333 01
Fax: +49 89 2000 33 2920